CHIP in Endothelial Dysfunction Associated With HEpEF

Inclusion Criteria: * HFpEF group and control group * male or female * 50 ≤ age ≤ 85 ans * Absence of evidence of hematological malignancy (known or obvious by the results of blood counts) * Subject registered with a social security scheme * Written informed consent obtained * HFpEF group * patients with a diagnosis of HFpEF according to the criteria defined by the European society of cardiology * Control group * patients with a neuro-cardiovascular pathology without any link to coronaropathy nor heart failure Exclusion Criteria: * Hematological malignancy (known or obvious on the results of blood counts) * Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal diseases) * Long term anti-inflammatory treatments: * Corticoids * Nonsteroidal anti-inflammatory drugs * Aspirin (\> 325 mg per day) * Cyclo-oxygenase II inhibitors * Persons under judicial safeguards, trustee or curatorship * Person deprived of judicial or administrative freedom * Person unable to give her consent * Non-cooperative person * Exclusion period after another clinical study or participation to another interventional clinical study testing a drug in the 30 days before inclusion